Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Perspective Article

KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s Disease

Author(s): Abdullah Al Mamun and Md. Sahab Uddin*

Volume 23 , Issue 9 , 2020

Page: [836 - 841] Pages: 6

DOI: 10.2174/1386207323666200117103144

Price: $65

[1]
Uddin, M.S.; Al Mamun, A.; Asaduzzaman, M.; Hosn, F.; Abu Sufian, M.; Takeda, S.; Herrera-Calderon, O.; Abdel-Daim, M.M.; Uddin, G.M.S.; Noor, M.A.A.; Begum, M.M.; Kabir, M.T.; Zaman, S.; Sarwar, M.S.; Rahman, M.M.; Rafe, M.R.; Hossain, M.F.; Hossain, M.S.; Ashraful Iqbal, M.; Sujan, M.A.R. Spectrum of disease and prescription pattern for outpatients with neurological disorders: an empirical pilot study in Bangladesh. Ann. Neurosci., 2018, 25(1), 25-37.
[http://dx.doi.org/10.1159/000481812] [PMID: 29887680]
[2]
Hossain, M.F.; Uddin, M.S.; Uddin, G.M.S.; Sumsuzzman, D.M.; Islam, M.S.; Barreto, G.E.; Mathew, B.; Ashraf, G.M. Melatonin in Alzheimer’s disease: a latent endogenous regulator of neurogenesis to mitigate Alzheimer’s neuropathology. Mol. Neurobiol., 2019, 56(12), 8255-8276.
[http://dx.doi.org/10.1007/s12035-019-01660-3] [PMID: 31209782]
[3]
Kabir, M.T.; Sufian, M.A.; Uddin, M.S.; Begum, M.M.; Akhter, S.; Islam, A.; Mathew, B.; Islam, M.S.; Amran, M.S.; Md Ashraf, G. NMDA receptor antagonists: repositioning of memantine as a multitargeting agent for Alzheimer’s therapy. Curr. Pharm. Des., 2019, 25(33), 3506-3518.
[http://dx.doi.org/10.2174/1381612825666191011102444] [PMID: 31604413]
[4]
Uddin, M.S.; Mamun, A.A.; Labu, Z.K.; Hidalgo-Lanussa, O.; Barreto, G.E.; Ashraf, G.M. Autophagic dysfunction in Alzheimer’s disease: Cellular and molecular mechanistic approaches to halt Alzheimer’s pathogenesis. J. Cell. Physiol., 2019, 234(6), 8094-8112.
[http://dx.doi.org/10.1002/jcp.27588] [PMID: 30362531]
[5]
Uddin, M.S.; Mamun, A.A.; Takeda, S.; Sarwar, M.S.; Begum, M.M. Analyzing the chance of developing dementia among geriatric people: a cross-sectional pilot study in Bangladesh. Psychogeriatrics, 2019, 19(2), 87-94.
[http://dx.doi.org/10.1111/psyg.12368] [PMID: 30221441]
[6]
Uddin, M.S.; Mamun, A.A.; Jakaria, M.; Thangapandiyan, S.; Ahmad, J.; Rahman, M.A.; Mathew, B.; Abdel-Daim, M.M.; Aleya, L. Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders. Sci. Total Environ., 2019, 707135624
[http://dx.doi.org/10.1016/j.scitotenv.2019.135624] [PMID: 31784171]
[7]
Uddin, M.S.; Amran, M.S. Handbook of Research on Critical Examinations of Neurodegenerative Disorders; IGI Global: USA, 2018.
[8]
Zaplatic, E.; Bule, M.; Shah, S.Z.A.; Uddin, M.S.; Niaz, K. Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer’s disease. Life Sci., 2019, 224, 109-119.
[http://dx.doi.org/10.1016/j.lfs.2019.03.055] [PMID: 30914316]
[9]
Golde, T.E.; Schneider, L.S.; Koo, E.H. Anti-aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift. Neuron, 2011, 69(2), 203-213.
[http://dx.doi.org/10.1016/j.neuron.2011.01.002] [PMID: 21262461]
[10]
Graham, W.V.; Bonito-Oliva, A.; Sakmar, T.P. Update on Alzheimer’s disease therapy and prevention strategies. Annu. Rev. Med., 2017, 68, 413-430.
[http://dx.doi.org/10.1146/annurev-med-042915-103753] [PMID: 28099083]
[11]
Schneider, L.S.; Mangialasche, F.; Andreasen, N.; Feldman, H.; Giacobini, E.; Jones, R.; Mantua, V.; Mecocci, P.; Pani, L.; Winblad, B.; Kivipelto, M. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J. Intern. Med., 2014, 275(3), 251-283.
[http://dx.doi.org/10.1111/joim.12191] [PMID: 24605808]
[12]
Sacks, C.A.; Avorn, J.; Kesselheim, A.S. The failure of Solanezumab - how the FDA saved taxpayers billions. N. Engl. J. Med., 2017, 376(18), 1706-1708.
[http://dx.doi.org/10.1056/NEJMp1701047] [PMID: 28467878]
[13]
Doody, R.S.; Thomas, R.G.; Farlow, M.; Iwatsubo, T.; Vellas, B.; Joffe, S.; Kieburtz, K.; Raman, R.; Sun, X.; Aisen, P.S.; Siemers, E.; Liu-Seifert, H.; Mohs, R. Alzheimer’s Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med., 2014, 370(4), 311-321.
[http://dx.doi.org/10.1056/NEJMoa1312889] [PMID: 24450890]
[14]
Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol., 2010, 9(7), 702-716.
[http://dx.doi.org/10.1016/S1474-4422(10)70119-8] [PMID: 20610346]
[15]
Kabir, M.T.; Uddin, M.S.; Begum, M.M.; Thangapandiyan, S.; Rahman, M.S.; Aleya, L.; Mathew, B.; Ahmed, M.; Barreto, G.E.; Ashraf, G.M. Cholinesterase inhibitors for Alzheimer’s disease: multitargeting strategy based on anti-Alzheimer’s drugs repositioning. Curr. Pharm. Des., 2019, 25(33), 3519-3535.
[http://dx.doi.org/10.2174/1381612825666191008103141] [PMID: 31593530]
[16]
Uddin, M.S.; Mamun, A.A.; Kabir, M.T.; Nasrullah, M.; Wahid, F.; Begum, M.M. Neurochemistry of neurochemicals: Messengers of brain functions. J. Intellect. Disabil. Diagnosis Treat., 2018, 5, 137-151.
[17]
Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch. Pharm. Res., 2013, 36(4), 375-399.
[http://dx.doi.org/10.1007/s12272-013-0036-3] [PMID: 23435942]
[18]
Birks, J.S. Cholinesterase inhibitors for Alzheimer’s disease.In: Cochrane Database of Systematic Reviews; Birks, J.S., Ed.; John Wiley & Sons, Ltd: Chichester, UK, 2006, p. CD005593.
[http://dx.doi.org/10.1002/14651858.CD005593]
[19]
Galisteo, M.; Rissel, M.; Sergent, O.; Chevanne, M.; Cillard, J.; Guillouzo, A.; Lagadic-Gossmann, D. Hepatotoxicity of tacrine: occurrence of membrane fluidity alterations without involvement of lipid peroxidation. J. Pharmacol. Exp. Ther., 2000, 294(1), 160-167.
[PMID: 10871308]
[20]
Lippincott Illustrated Reviews Pharmacology. Karen Whalen; Wolters Kluwer: USA, 2018.
[21]
Uddin, M.S.; Upaganlawar, A.B. Oxidative Stress and Antioxidant Defense: Biomedical Value in Health and Diseases; Nova Science Publishers: USA, 2019.
[22]
Mathew, B.; Baek, S.C.; Thomas Parambi, D.G.; Lee, J.P.; Mathew, G.E.; Jayanthi, S.; Vinod, D.; Rapheal, C.; Devikrishna, V.; Kondarath, S.S.; Uddin, M.S.; Kim, H. Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: Fluorinated chalcones of morpholine versus imidazole. Arch. Pharm. (Weinheim), 2019, 352(4)e1800309
[http://dx.doi.org/10.1002/ardp.201800309] [PMID: 30663112]
[23]
Mathew, B.; Parambi, D.G.T.; Mathew, G.E.; Uddin, M.S.; Inasu, S.T.; Kim, H. Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer’s and Parkinson’s diseases. Arch. Pharm. (Weinheim), 2019, 3521900177
[http://dx.doi.org/10.1002/ardp.201900177]
[24]
Isbister, G.K.; Hackett, L.P.; Dawson, A.H.; Whyte, I.M.; Smith, A.J. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br. J. Clin. Pharmacol., 2003, 56(4), 441-450.
[http://dx.doi.org/10.1046/j.1365-2125.2003.01895.x] [PMID: 12968990]
[25]
Borroni, E.; Bohrmann, B.; Grueninger, F.; Prinssen, E.; Nave, S.; Loetscher, H.; Chinta, S.J.; Rajagopalan, S.; Rane, A.; Siddiqui, A.; Ellenbroek, B.; Messer, J.; Pähler, A.; Andersen, J.K.; Wyler, R.; Cesura, A.M. Sembragiline: a novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer’s disease. J. Pharmacol. Exp. Ther., 2017, 362(3), 413-423.
[http://dx.doi.org/10.1124/jpet.117.241653] [PMID: 28642233]
[26]
Jo, S.; Yarishkin, O.; Hwang, Y.J.; Chun, Y.E.; Park, M.; Woo, D.H.; Bae, J.Y.; Kim, T.; Lee, J.; Chun, H.; Park, H.J.; Lee, D.Y.; Hong, J.; Kim, H.Y.; Oh, S.J.; Park, S.J.; Lee, H.; Yoon, B.E.; Kim, Y.; Jeong, Y.; Shim, I.; Bae, Y.C.; Cho, J.; Kowall, N.W.; Ryu, H.; Hwang, E.; Kim, D.; Lee, C.J. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat. Med., 2014, 20(8), 886-896.
[http://dx.doi.org/10.1038/nm.3639] [PMID: 24973918]
[27]
Yoon, B-E.; Woo, J.; Chun, Y-E.; Chun, H.; Jo, S.; Bae, J.Y.; An, H.; Min, J.O.; Oh, S.J.; Han, K.S.; Kim, H.Y.; Kim, T.; Kim, Y.S.; Bae, Y.C.; Lee, C.J. Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition. J. Physiol., 2014, 592(22), 4951-4968.
[http://dx.doi.org/10.1113/jphysiol.2014.278754] [PMID: 25239459]
[28]
Sano, M.; Ernesto, C.; Thomas, R.G.; Klauber, M.R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C.W.; Pfeiffer, E.; Schneider, L.S.; Thal, L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med., 1997, 336(17), 1216-1222.
[http://dx.doi.org/10.1056/NEJM199704243361704] [PMID: 9110909]
[29]
Mangoni, A.; Grassi, M.P.; Frattola, L.; Piolti, R.; Bassi, S.; Motta, A.; Marcone, A.; Smirne, S. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur. Neurol., 1991, 31(2), 100-107.
[http://dx.doi.org/10.1159/000116655] [PMID: 1904354]
[30]
Piccinin, G.L.; Finali, G.; Piccirilli, M. Neuropsychological effects of L-deprenyl in Alzheimer’s type dementia. Clin. Neuropharmacol., 1990, 13(2), 147-163.
[http://dx.doi.org/10.1097/00002826-199004000-00004] [PMID: 2109658]
[31]
Froestl, W.; Muhs, A.; Pfeifer, A. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014. J. Alzheimers Dis., 2014, 42(1), 1-68.
[http://dx.doi.org/10.3233/JAD-140402] [PMID: 24903780]
[32]
Wilcock, G.K.; Birks, J.; Whitehead, A.; Evans, S.J.G. The effect of selegiline in the treatment of people with Alzheimer’s disease: a meta-analysis of published trials. Int. J. Geriatr. Psychiatry, 2002, 17(2), 175-183.
[http://dx.doi.org/10.1002/gps.545] [PMID: 11813282]
[33]
Park, J-H.; Ju, Y.H.; Choi, J.W.; Song, H.J.; Jang, B.K.; Woo, J.; Chun, H.; Kim, H.J.; Shin, S.J.; Yarishkin, O.; Jo, S.; Park, M.; Yeon, S.K.; Kim, S.; Kim, J.; Nam, M.H.; Londhe, A.M.; Kim, J.; Cho, S.J.; Cho, S.; Lee, C.; Hwang, S.Y.; Kim, S.W.; Oh, S.J.; Cho, J.; Pae, A.N.; Lee, C.J.; Park, K.D. Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease. Sci. Adv., 2019, 5(3)eaav0316
[http://dx.doi.org/10.1126/sciadv.aav0316] [PMID: 30906861]
[34]
Fowler, J.S.; Volkow, N.D.; Logan, J.; Wang, G.J.; MacGregor, R.R.; Schyler, D.; Wolf, A.P.; Pappas, N.; Alexoff, D.; Shea, C. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse, 1994, 18(2), 86-93.
[http://dx.doi.org/10.1002/syn.890180203] [PMID: 7839316]
[35]
Kim, J.I.; Ganesan, S.; Luo, S.X.; Wu, Y.W.; Park, E.; Huang, E.J. Aldehyde dehydrogenase 1a1 mediates a GABA synthesis pathway in midbrain dopaminergic neurons. Science, 2015, 350(6256), 102-106.
[36]
Marzo, A.; Dal Bo, L.; Monti, N.C.; Crivelli, F.; Ismaili, S.; Caccia, C.; Cattaneo, C.; Fariello, R.G. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol. Res., 2004, 50(1), 77-85.
[http://dx.doi.org/10.1016/j.phrs.2003.12.004] [PMID: 15082032]
[37]
Choi, J.W.; Jang, B.K.; Cho, N.C.; Park, J.H.; Yeon, S.K.; Ju, E.J. Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorg. Med. Chem., 2015, 23, 6486-6496.
[http://dx.doi.org/10.1016/j.bmc.2015.08.012]
[38]
Nam, M.H.; Park, M.; Park, H.; Kim, Y.; Yoon, S.; Sawant, V.S.; Choi, J.W.; Park, J.H.; Park, K.D.; Min, S.J.; Lee, C.J.; Choo, H. Indole-substituted benzothiazoles and benzoxazoles as selective and reversible MAO-B inhibitors for treatment of Parkinson’s disease. ACS Chem. Neurosci., 2017, 8(7), 1519-1529.
[http://dx.doi.org/10.1021/acschemneuro.7b00050] [PMID: 28332824]
[39]
Nave, S.; Doody, R.S.; Boada, M.; Grimmer, T.; Savola, J.M.; Delmar, P.; Pauly-Evers, M.; Nikolcheva, T.; Czech, C.; Borroni, E.; Ricci, B.; Dukart, J.; Mannino, M.; Carey, T.; Moran, E.; Gilaberte, I.; Muelhardt, N.M.; Gerlach, I.; Santarelli, L.; Ostrowitzki, S.; Fontoura, P. Sembragiline in moderate Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase II trial (MAyflOwer RoAD). J. Alzheimers Dis., 2017, 58(4), 1217-1228.
[http://dx.doi.org/10.3233/JAD-161309] [PMID: 28550255]
[40]
Li, Y.; Sun, H.; Chen, Z.; Xu, H.; Bu, G.; Zheng, H. Implications of GABAergic neurotransmission in Alzheimer’s disease. Front. Aging Neurosci., 2016, 8, 31.
[http://dx.doi.org/10.3389/fnagi.2016.00031] [PMID: 26941642]
[41]
Schedin-Weiss, S.; Inoue, M.; Hromadkova, L.; Teranishi, Y.; Yamamoto, N.G.; Wiehager, B.; Bogdanovic, N.; Winblad, B.; Sandebring-Matton, A.; Frykman, S.; Tjernberg, L.O. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels. Alzheimers Res. Ther., 2017, 9(1), 57.
[http://dx.doi.org/10.1186/s13195-017-0279-1] [PMID: 28764767]
[42]
Barres, B.A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron, 2008, 60(3), 430-440.
[http://dx.doi.org/10.1016/j.neuron.2008.10.013] [PMID: 18995817]
[43]
Sofroniew, M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci., 2009, 32(12), 638-647.
[http://dx.doi.org/10.1016/j.tins.2009.08.002] [PMID: 19782411]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy